hTNF-α基因转导的小鼠肝癌细胞株H22的某些生物学行为  

Study on Biologic Behavior of hTNF-α Gene Modified H22 Cells in Vitro

作　　者：孙欲晓[1] 张腾飞[1] 陈诗书[1] 

机构地区：[1]上海第二医科大学人类基因治疗研究中心,200025

出　　处：《胃肠病学》1999年第1期8-10,共3页Chinese Journal of Gastroenterology

基　　金：国家自然科学基金!(资助号:39370792);"863"重点课题基金资助!(资助号:863-Z20-01-02)

摘　　要：目的：为制备有效的细胞因子基因修饰瘤苗，观察人肿瘤坏死因子α（ｈＴＮＦ－α）基因修饰前后是否有生物学行为的改变。方法：将含信号肽的ｈＴＮＦ－α ｃＤＮＡ基因用逆转录病毒载体导入小鼠肝癌细胞株Ｈ２２中，用Ｇ４１８筛选、克隆和扩增。经分子生物学方法和细胞生物学方法对基因修饰的正确性、表达和分泌进行了鉴定。结果：ｈＴＮＦ－α基因整合至Ｈ２２细胞基因组ＤＮＡ中，未发生重排，并表达外源ｈＴＮＦ－α。ｈＴＮＦ－α基因修饰的肿瘤细胞表面形态有很大的变化。有些经ｈＴＮＦ－α基因修饰的Ｈ２２克隆，Ｈ－２Ｉ类抗原表达增强，提高肿瘤细胞免疫原性，间接诱导机体抗肿瘤免疫。结论：为进一步选择较好的Ｈ２２－ｈＴＮＦ－α克隆进行动物体内试验打下基础。Background/Aims: To gain the effective cytokine gene modified tumor vaccine and to observe its changes of biologic behavior. Methods: To test the integratement of hTNF-α gene, its expression and secretion, and to observe the surface structure of cells by technique of molecular cell biology. Results: hTNF-a gene was integrated into the H22 cells genome and not rearranged and was expressed in modified H22 cells, which have a great change in their surface structure. Some clones improve the expression of H-2 I antigen, which enhance the immunogenicity of tumor cells and induce anti-tumor immunoresponse indirectly. Conclusions: These studies are useful to choose the better H22-hTNF-α clones to research in tumor gene therapy in vivo.

关 键 词：肝癌 瘤苗 基因治疗 人肿瘤坏死因子Α 免疫原性 

分 类 号：R735.7[医药卫生—肿瘤]